Breakthrough Bleeding - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Breakthrough Bleeding

The Experts below are selected from a list of 225 Experts worldwide ranked by ideXlab platform

Thomas J Kuehl – 1st expert on this subject based on the ideXlab platform

  • frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring a randomized controlled trial
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P<.02). Most patients had no to minimal Bleeding during continuous use with group 2 experiencing a statistically greater percentage of days without Breakthrough Bleeding or spotting (95%) compared with group 1 (89%) (P=.016). Instituting a 4-day hormone-free interval was more (P<.001) effective in resolving Breakthrough Bleeding/spotting than continuing ring use. CONCLUSION: A reduction in Bleeding occurred during continuous use with replacement of the transvaginal ring compared with baseline 21/7 use. Continuous vaginal ring use resulted in an acceptable Bleeding profile in most patients reduction in flow reduction in pelvic pain and a high continuation rate.

  • Frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P

  • prospective analysis of occurrence and management of Breakthrough Bleeding during an extended oral contraceptive regimen
    American Journal of Obstetrics and Gynecology, 2006
    Co-Authors: Patricia J Sulak, Thomas J Kuehl, Andrea Coffee, Sherilyn Willis

    Abstract:

    Objective The purpose of this study was to assess the Bleeding patterns of an extended oral contraceptive (OC) regimen and management of Breakthrough Bleeding/Breakthrough spotting (BTB/BTS). Study design This was a single-center prospective analysis of self-rated menstrual flow during a 21/7-day versus a 168-day extended regimen of on OC containing 3 mg of drosperinone and 30 mcg of ethinyl estradiol (DRSP/EE) with institution of a randomized protocol to manage BTB/BTS. Results Of the 111 patients initiating the extended OC regimen, 102 (92%) completed the 168-day regimen. Subjects having a heavier daily flow rating during the 21/7-day pre-extension cycle had greater daily flow ratings ( P P = .07) than subjects with lighter daily flow ratings. If BTB/BTS of at least 7 consecutive days occurred, patients were randomized to taking a 3-day hormone free interval (HFI) versus continuing active pills. Instituting a 3-day HFI was significantly more effective in resolving BTB/BTS than continuing active pills ( P P = .53). Conclusion A 168-day extended regimen of DRSP/EE had an acceptable Bleeding profile with a high continuation rate. Bleeding during the extended cycle was effectively managed with institution of a 3-day HFI.

Patricia J Sulak – 2nd expert on this subject based on the ideXlab platform

  • frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring a randomized controlled trial
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P<.02). Most patients had no to minimal Bleeding during continuous use with group 2 experiencing a statistically greater percentage of days without Breakthrough Bleeding or spotting (95%) compared with group 1 (89%) (P=.016). Instituting a 4-day hormone-free interval was more (P<.001) effective in resolving Breakthrough Bleeding/spotting than continuing ring use. CONCLUSION: A reduction in Bleeding occurred during continuous use with replacement of the transvaginal ring compared with baseline 21/7 use. Continuous vaginal ring use resulted in an acceptable Bleeding profile in most patients reduction in flow reduction in pelvic pain and a high continuation rate.

  • Frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P

  • prospective analysis of occurrence and management of Breakthrough Bleeding during an extended oral contraceptive regimen
    American Journal of Obstetrics and Gynecology, 2006
    Co-Authors: Patricia J Sulak, Thomas J Kuehl, Andrea Coffee, Sherilyn Willis

    Abstract:

    Objective The purpose of this study was to assess the Bleeding patterns of an extended oral contraceptive (OC) regimen and management of Breakthrough Bleeding/Breakthrough spotting (BTB/BTS). Study design This was a single-center prospective analysis of self-rated menstrual flow during a 21/7-day versus a 168-day extended regimen of on OC containing 3 mg of drosperinone and 30 mcg of ethinyl estradiol (DRSP/EE) with institution of a randomized protocol to manage BTB/BTS. Results Of the 111 patients initiating the extended OC regimen, 102 (92%) completed the 168-day regimen. Subjects having a heavier daily flow rating during the 21/7-day pre-extension cycle had greater daily flow ratings ( P P = .07) than subjects with lighter daily flow ratings. If BTB/BTS of at least 7 consecutive days occurred, patients were randomized to taking a 3-day hormone free interval (HFI) versus continuing active pills. Instituting a 3-day HFI was significantly more effective in resolving BTB/BTS than continuing active pills ( P P = .53). Conclusion A 168-day extended regimen of DRSP/EE had an acceptable Bleeding profile with a high continuation rate. Bleeding during the extended cycle was effectively managed with institution of a 3-day HFI.

Andrea Coffee – 3rd expert on this subject based on the ideXlab platform

  • frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring a randomized controlled trial
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P<.02). Most patients had no to minimal Bleeding during continuous use with group 2 experiencing a statistically greater percentage of days without Breakthrough Bleeding or spotting (95%) compared with group 1 (89%) (P=.016). Instituting a 4-day hormone-free interval was more (P<.001) effective in resolving Breakthrough Bleeding/spotting than continuing ring use. CONCLUSION: A reduction in Bleeding occurred during continuous use with replacement of the transvaginal ring compared with baseline 21/7 use. Continuous vaginal ring use resulted in an acceptable Bleeding profile in most patients reduction in flow reduction in pelvic pain and a high continuation rate.

  • Frequency and management of Breakthrough Bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.
    Obstetrics & Gynecology, 2008
    Co-Authors: Patricia J Sulak, Virginia J Smith, Andrea Coffee, Iris Witt, Alicia L Kuehl, Thomas J Kuehl

    Abstract:

    OBJECTIVE: To assess Bleeding patterns with continuous use of the transvaginal contraceptive ring. METHODS: We did a prospective analysis of daily menstrual flow during a 21/7 cycle followed by 6 months of continuous use and institution of a randomized protocol to manage Breakthrough Bleeding/spotting. Seventy-four women completed the baseline 21/7 phase and were randomized equally into two groups during the continuous phase. Group 1 was instructed to replace the ring monthly on the same calendar day with no ring-free days. Group 2 was instructed to use the same process but if Breakthrough Bleeding/spotting occurred for 5 days or more they were to remove the ring for 4 days store it and then reinsert that ring. RESULTS: Sixty-five women completed the continuous phase with reduced average flow scores in the continuous phase compared with the 21/7 phase (P

  • prospective analysis of occurrence and management of Breakthrough Bleeding during an extended oral contraceptive regimen
    American Journal of Obstetrics and Gynecology, 2006
    Co-Authors: Patricia J Sulak, Thomas J Kuehl, Andrea Coffee, Sherilyn Willis

    Abstract:

    Objective The purpose of this study was to assess the Bleeding patterns of an extended oral contraceptive (OC) regimen and management of Breakthrough Bleeding/Breakthrough spotting (BTB/BTS). Study design This was a single-center prospective analysis of self-rated menstrual flow during a 21/7-day versus a 168-day extended regimen of on OC containing 3 mg of drosperinone and 30 mcg of ethinyl estradiol (DRSP/EE) with institution of a randomized protocol to manage BTB/BTS. Results Of the 111 patients initiating the extended OC regimen, 102 (92%) completed the 168-day regimen. Subjects having a heavier daily flow rating during the 21/7-day pre-extension cycle had greater daily flow ratings ( P P = .07) than subjects with lighter daily flow ratings. If BTB/BTS of at least 7 consecutive days occurred, patients were randomized to taking a 3-day hormone free interval (HFI) versus continuing active pills. Instituting a 3-day HFI was significantly more effective in resolving BTB/BTS than continuing active pills ( P P = .53). Conclusion A 168-day extended regimen of DRSP/EE had an acceptable Bleeding profile with a high continuation rate. Bleeding during the extended cycle was effectively managed with institution of a 3-day HFI.